[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF: AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis; 2008;18(2 Suppl 2):S2-189-94
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.
  • Implementation of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the HIV/AIDS morbidity and mortality.
  • The present study evaluates the neoplasm prevalence before and after the implementation of HAART.
  • Neoplasm prevalence was measured, and the difference in AIDS- and non-AIDS-defining neoplasms was analyzed before and after the HAART era.
  • Of these, 51.5% were AIDS-defining neoplasms, and 68% were established before HAART.
  • AIDS-defining neoplasms accounted for 62.4% of those detected before the availability of HAART and 25.9% of those detected after HAART.
  • Except for cervical carcinoma, the prevalence of AIDS-defining neoplasms decreased after HAART.
  • Non-AIDS lymphomas and prostate neoplasms were more frequent after HAART.
  • DISCUSSION: Our study found a significant reduction of Kaposi sarcoma and AIDS-related lymphoma in the HAART era of the AIDS epidemic.
  • A higher prevalence of non-AIDS-defining lymphomas, prostate carcinoma, and cervical carcinoma was seen in the HAART era.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2006 Nov;61(11):1000-8 [17071836.001]
  • [Cites] MMWR Suppl. 1987 Aug 14;36(1):1S-15S [3039334.001]
  • [Cites] J Behav Med. 2007 Oct;30(5):371-83 [17570050.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2417-9 [16735700.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):223-8 [10889597.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):480-2 [11391169.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Oct 17;17(15):2227-36 [14523280.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-57-62 [16312941.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1030-8 [12684916.001]
  • (PMID = 18646347.001).
  • [ISSN] 1049-510X
  • [Journal-full-title] Ethnicity & disease
  • [ISO-abbreviation] Ethn Dis
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / G12 MD007583; United States / NCRR NIH HHS / RR / U54 RR019507; United States / NCRR NIH HHS / RR / G12RR03035; United States / NCRR NIH HHS / RR / 1U54RR01950701; United States / NCRR NIH HHS / RR / G12 RR003035
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS425729; NLM/ PMC3546505
  •  go-up   go-down


2. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


3. Roma AA, Goldblum JR, Fazio V, Yang B: Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma. Int J Clin Exp Pathol; 2008;1(5):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma.
  • 14-3-3sigma is a p53-regulated G2/M inhibitor involved in numerous cellular signaling pathways related to cell cycle, DNA repair and apoptosis.
  • However, the expression of 14-3-3sigma protein has not yet been studied in anal SCC and its precursor, anal intraepithelial neoplasm (AIN).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):429-41 [10716158.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] J Low Genit Tract Dis. 2007 Jan;11(1):46-7 [17194951.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4353-7 [10969776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3105-10 [16886641.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):225-34 [16697215.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):161 [16697214.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):785-95 [15778465.001]
  • [Cites] Histopathology. 2005 Jun;46(6):718-20 [15910611.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):108-13 [15870532.001]
  • [Cites] Cell Res. 2005 Apr;15(4):228-36 [15857577.001]
  • [Cites] Pathol Int. 2005 Feb;55(2):77-82 [15693853.001]
  • [Cites] AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91 [15712398.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1477-83 [15619206.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1591-7 [15547695.001]
  • [Cites] Semin Cancer Biol. 1998;8(5):345-57 [10101800.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):743-50 [15482563.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1131-8 [15292943.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):206-14 [15213596.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2687-93 [15102672.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1876-81 [11896620.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45193-200 [11577088.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jan;20(1):16-30 [11192069.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • (PMID = 18787619.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480570
  • [Keywords] NOTNLM ; 14-3-3σ / AIN / Anal intraepithelial neoplasm / Bowenoid / differentiated / p16 / p53 / simplex
  •  go-up   go-down


Advertisement
4. Huysentruyt LC, McGrath MS: The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol; 2010 Apr;87(4):627-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.
  • Additionally, TAM are known to promote tumor progression for most cancer types, including lymphomas.


5. Lim ST, Tupule A, Espina BM, Levine AM: Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer; 2005 Jan 15;103(2):417-21
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
  • BACKGROUND: Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
  • CONCLUSIONS: Weekly docetaxel is safe, with reasonable antitumor activity in patients with advanced-stage, recurrent, or refractory AIDS-related KS.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome


6. Capalbo G, Müller-Kuller T, Dietrich U, Hoelzer D, Ottmann OG, Scheuring UJ: Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression. Retrovirology; 2010;7:26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.
  • BACKGROUND: Previously, we showed that glioma pathogenesis related protein (GliPR) is induced in CEM T cells upon HIV-1 infection in vitro.
  • [MeSH-major] Antiviral Agents / pharmacology. Biological Products / pharmacology. HIV-1 / physiology. Neoplasm Proteins / antagonists & inhibitors. Nerve Tissue Proteins / antagonists & inhibitors. RNA, Small Interfering / pharmacology. Virus Replication

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2000 Jan 5;266(1):8-16 [10612655.001]
  • [Cites] Exp Hematol. 2000 Jan;28(1):65-76 [10658678.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8849-55 [10922045.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3254-61 [11024024.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2396-405 [11704662.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3345-57 [11971968.001]
  • [Cites] Nat Med. 2002 Jul;8(7):681-6 [12042777.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9380-5 [12089333.001]
  • [Cites] BMC Biochem. 2002 Jun 10;3:14 [12069692.001]
  • [Cites] Blood. 2003 Jan 1;101(1):85-90 [12393581.001]
  • [Cites] Hum Gene Ther. 2003 Jan 20;14(2):91-101 [12614561.001]
  • [Cites] Immunol Res. 2003;27(2-3):247-60 [12857972.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31105-10 [12759345.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35211-9 [12842892.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 20;314(4):1126-32 [14751250.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):969-76 [14871827.001]
  • [Cites] AIDS. 2004 Mar 5;18(4):587-96 [15090763.001]
  • [Cites] J Mol Biol. 2004 May 21;339(1):173-83 [15123429.001]
  • [Cites] J Virol. 2004 Sep;78(17):9458-73 [15308739.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1165-70 [2182321.001]
  • [Cites] J Virol. 1992 May;66(5):2814-20 [1560526.001]
  • [Cites] J Virol Methods. 1992 Sep;39(1-2):15-26 [1430060.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4792-6 [7876252.001]
  • [Cites] Gene. 1995 Jun 14;159(1):131-5 [7607567.001]
  • [Cites] Mol Reprod Dev. 1996 Jun;44(2):221-9 [9115720.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):125-30 [8973356.001]
  • [Cites] FEBS Lett. 1997 Mar 17;405(1):68-72 [9094426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2262-6 [9482873.001]
  • [Cites] AIDS. 1998 Apr 16;12(6):563-70 [9583595.001]
  • [Cites] AIDS. 1999 Feb 4;13(2):167-75 [10202822.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6858-63 [15557180.001]
  • [Cites] Annu Rev Genet. 2004;38:61-85 [15568972.001]
  • [Cites] Curr HIV Res. 2005 Jan;3(1):87-94 [15638726.001]
  • [Cites] Jpn J Infect Dis. 2005 Jun;58(3):125-30 [15973003.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:916-23 [15719026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10200-5 [16009940.001]
  • [Cites] Retrovirology. 2005;2:63 [16232320.001]
  • [Cites] Mol Cells. 2006 Feb 28;21(1):7-20 [16511342.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4139-48 [16618735.001]
  • [Cites] Cancer Gene Ther. 2006 Jul;13(7):658-63 [16485011.001]
  • [Cites] J Leukoc Biol. 2006 Nov;80(5):973-83 [16908514.001]
  • [Cites] Annu Rev Phytopathol. 2006;44:135-62 [16602946.001]
  • [Cites] Intervirology. 2007;50(3):224-8 [17356300.001]
  • [Cites] Retrovirology. 2007;4:41 [17565699.001]
  • [Cites] Retrovirology. 2007;4:52 [17651505.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):970-8 [18030365.001]
  • [Cites] Science. 2008 Feb 15;319(5865):921-6 [18187620.001]
  • [Cites] Retrovirology. 2008;5:8 [18226242.001]
  • [Cites] Retrovirology. 2008;5:19 [18261236.001]
  • [Cites] Mol Immunol. 2008 May;45(10):2905-19 [18342939.001]
  • [Cites] J Virol. 2000 Apr;74(7):3264-72 [10708443.001]
  • (PMID = 20356381.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biological Products; 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2859388
  •  go-up   go-down


7. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature; 2008 Jul 24;454(7203):436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-related inflammation.
  • In some types of cancer, inflammatory conditions are present before a malignant change occurs.
  • Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours.
  • It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents.
  • The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
  • [MeSH-minor] Gonadal Steroid Hormones / metabolism. Humans. Leukocytes / immunology. Leukocytes / metabolism. Neoplasm Invasiveness. Oncogenes / genetics. Oncogenes / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650914.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 98
  •  go-up   go-down


8. Lavolé A, Epaud C, Rosencher L, Gounant V, Wislez M, Cadranel J: [Lung cancer in HIV-positive patients]. Rev Pneumol Clin; 2007 Jun;63(3):167-75
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in HIV-positive patients].
  • [Transliterated title] Le cancer broncho-pulmonaire chez les patients séropositifs pour le virus de l'immunodéficience humaine.
  • Since 1996, AIDS-related mortality has declined considerably with the introduction of tritherapy (HAART).
  • This decline in mortality has been associated with an increase in the proportion of deaths caused by cancers unrelated to AIDS, particularly lung cancer.
  • The risk of developing lung cancer is higher in the HIV-seropositive population than in the aged-matched general population, undoubtedly because of the high rate of smoking, particularly among drug abusers, but also because of other reasons which remain to be determined.
  • Mean age at the discovery of lung cancer in HIV+ patients is 45 years, and most are symptomatic.
  • Prospective clinical studies are needed to define a better management strategy for lung cancer in HIV-positive patients.
  • [MeSH-minor] Adenocarcinoma / complications. Age Factors. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Humans. Neoplasm Staging. Pneumonectomy. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675940.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


9. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U: AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res; 2009 Nov;7(6):634-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies.
  • In the HAART era Kaposi's sarcoma (KS) remains the second most frequent tumor in HIV-infected patients worldwide, and it has become the most common cancer in Sub-Saharan Africa.
  • KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate, which suggests that KS may result from reactive hyperproliferation induced by chronic inflammation, and therefore it is not a true neoplasm.
  • Treatment decisions must take into consideration the extent and the rate of tumor growth, patient's symptoms, immune system conditions and concurrent HIV-related complications.
  • The aim of this article is to provide an up-to-date review of the current status and perspectives of AIDS-related KS in the HAART era.


10. Mbulaiteye SM, Sternberg LR, Nsubuga MM, Anver MR, Mehta M, Biryahwaho B, Kambugu F, Rabkin CS, Biggar RJ: Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma. Cancer Lett; 2007 Apr 18;248(2):229-33
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma.
  • Kaposi sarcoma (KS) occurs with relatively high frequency in immunosuppressed transplant recipients and in patients with AIDS.
  • Recently, Italian investigators reported transplant-related KS tumors bearing donor-derived antigens, suggesting possible parenteral transmission of KS as whole cells, i.e., chimeric tumors.
  • To investigate the hypothesis that KS whole cells may also be transmitted into immunocompromised persons via heterosexual acts, we tested nodular KS lesions and matched normal tissue obtained from female patients with AIDS for the presence of the Y-chromosome specific sex determining sequence (SRY).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. DNA, Neoplasm / genetics. Disease Transmission, Infectious. Sarcoma, Kaposi / genetics. Sex-Determining Region Y Protein / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16934394.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


11. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


12. Hernández-Morales DE, Hernández-Zaccaro AE: Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions. Eur J Cancer Care (Engl); 2005 Jul;14(3):264-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
  • Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients.
  • The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952971.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


13. Seoane Lestón J, Diz Dios P: Diagnostic clinical aids in oral cancer. Oral Oncol; 2010 Jun;46(6):418-22
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic clinical aids in oral cancer.
  • Conventional oral exploration (visual and palpation examination) constitutes the current gold standard for oral cancer screening, while biopsy and histopathological examination represents the indispensable study for the detection of cases in patients with an identified lesion.
  • There are also a number of techniques that may contribute to the diagnosis of oral cancer: toluidine blue test has been used as a diagnostic aid for the detection of oral cancer over decades.
  • In the near future, immunological and biochemical alterations in the serum (e.g., circulating immune complexes, carcinoembryonic antigen, squamous cell carcinoma associated antigen, inhibitor of apoptosis, cytokeratin fragments, and annexin A1) as well as specific saliva analysis (e.g., cancer related cytokines, metalloproteinases, epithelial tumour markers, DNA promoter hypermethylation, and saliva micro-RNA) may become important tools for the detection of oral cancer.
  • [MeSH-minor] Female. Humans. Male. Mouth Mucosa / pathology. Neoplasm Staging. Physical Examination. Saliva / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20371204.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride
  •  go-up   go-down


14. Rajput S, Wilber A: Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed); 2010;2:176-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of inflammation in cancer initiation, progression, and metastasis.
  • Inflammatory cells and signals contribute to the initiation and development of cancer.
  • In fact, persistent inflammatory conditions resulting from infection or injury can exist before a normal cell is transformed into a cancer cell.
  • Alternatively, cancer development unrelated to inflammation can stimulate the development of an inflammatory microenvironment that promotes tumor cell proliferation.
  • Whether chronic or tumor-derived, inflammation and inflammation-related stimuli within the tumor microenvironment permits proliferation and survival of cancer cells, promotes blood and lymphatic vessel formation, and aids in invasion and metastasis.
  • The inflammatory status of the tumor microenvironment can act to quell the body's natural immune response and effectively ameliorate a positive response to many commonly used anti-cancer antibodies and chemotherapeutic agents.
  • New evidence suggests that the molecular pathways and consequences of inflammation specifically related to the tumor microenvironment are starting to be understood.
  • [MeSH-major] Cytokines / metabolism. Inflammation / complications. Neoplasm Metastasis / physiopathology. Neoplasms / etiology. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20036938.001).
  • [ISSN] 1945-0524
  • [Journal-full-title] Frontiers in bioscience (Scholar edition)
  • [ISO-abbreviation] Front Biosci (Schol Ed)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hypoxia-Inducible Factor 1; 0 / NF-kappa B; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


15. Sharma R, Iyer M: Bowen's disease of the nipple in a young man with AIDS: a case report. Clin Breast Cancer; 2009 Feb;9(1):53-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease of the nipple in a young man with AIDS: a case report.
  • Bowen's disease, or squamous cell carcinoma in situ (SCCIS) of the skin, is a malignant neoplasm restricted to the epidermis, without evidence of dermal invasion.
  • With the advent of highly active antiretroviral treatment, chronic non-HIV related conditions have become more important, male breast cancer being one of them.


16. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C: FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging; 2010 Dec;54(6):698-703
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging.
  • AIM: The incidence of non-AIDS-related cancers (NADCs) in the AIDS-population has surpassed that of the general population.
  • In addition, 30 consecutively referred, previously untreated, HIV and TB negative cancer patients were included.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasms / metabolism. Neoplasms / pathology. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150859.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer; 2010 Mar 16;102(6):1003-9
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
  • BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer.
  • METHODS: Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2.
  • CONCLUSION: Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.
  • [MeSH-minor] Aryl Hydrocarbon Hydroxylases / genetics. Biomarkers, Pharmacological / analysis. Biomarkers, Tumor / genetics. Cytochrome P-450 CYP2B6. Drug Resistance, Neoplasm / genetics. Drug-Related Side Effects and Adverse Reactions / genetics. Female. Gene Frequency. Genotype. Humans. Middle Aged. Organic Cation Transport Proteins / genetics. Oxidoreductases, N-Demethylating / genetics. P-Glycoprotein / genetics. P-Glycoproteins. Polymorphism, Single Nucleotide. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827860887 for PMID:20179710 [PharmGKB] .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 2001 Aug;70(2):189-99 [11503014.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):447-58 [11470997.001]
  • [Cites] Drug Metab Dispos. 2003 Apr;31(4):398-403 [12642465.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2202-10 [15248218.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5141-8 [2441861.001]
  • [Cites] Biochim Biophys Acta. 1988 Aug 3;948(1):87-128 [2899442.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1483-96 [2202791.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5629-37 [8242617.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15419-22 [8195181.001]
  • [Cites] Pharmacogenetics. 1997 Jun;7(3):211-21 [9241661.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):389-98 [9516927.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Lancet. 1999 Feb 27;353(9154):717-9 [10073515.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):655-66 [10348794.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Trends Pharmacol Sci. 1999 Aug;20(8):342-9 [10431214.001]
  • [Cites] AIDS. 2004 Dec 3;18(18):2391-400 [15622315.001]
  • [Cites] Drug Metab Dispos. 2005 Feb;33(2):254-7 [15537833.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):754-62 [15963465.001]
  • [Cites] Pharmacogenomics J. 2005;5(6):365-73 [16116487.001]
  • [Cites] Eur J Pharm Sci. 2006 Jan;27(1):54-61 [16183265.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Pharmacogenet Genomics. 2007 Feb;17(2):127-36 [17301692.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):431-45 [17502835.001]
  • [Cites] Pharmacogenomics. 2007 Jun;8(6):567-75 [17559346.001]
  • [Cites] Lancet. 2008 Jan 5;371(9606):29-40 [18177773.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):515-23 [18496131.001]
  • [Cites] Br J Clin Pharmacol. 2009 Jan;67(1):50-60 [19076156.001]
  • [Cites] J Antimicrob Chemother. 2009 Apr;63(4):841-3 [19218571.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar16;281(5):1256-60 [11243870.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):399-415 [11470993.001]
  • [Cites] Pharmacogenomics J. 2003;3(1):53-61 [12629583.001]
  • (PMID = 20179710.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Pharmacological; 0 / Biomarkers, Tumor; 0 / Organic Cation Transport Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / SLC22A16 protein, human; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  • [Other-IDs] NLM/ PMC2844036
  •  go-up   go-down


18. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


19. Handisurya A, Rieger A, Bankier A, Koller A, Salat A, Stingl G, Kirnbauer R: Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy. Br J Dermatol; 2007 Oct;157(4):788-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.
  • Classification of HPV 26 as high- or intermediate-risk type has been uncertain, due to its rare presence in cervical cancer.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Alphapapillomavirus / classification. Carcinoma, Squamous Cell / virology. Nails. Papillomavirus Infections / complications. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Disease Progression. Fingers / diagnostic imaging. Fingers / pathology. Humans. Male. Neoplasm Invasiveness. Radiography

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HPV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):388-94 [15245440.001]
  • [Cites] J Invest Dermatol. 1984 Apr;82(4):362-6 [6323588.001]
  • [Cites] J Virol. 1986 Feb;57(2):688-92 [3003400.001]
  • [Cites] Laryngoscope. 1993 Mar;103(3):253-7 [8382761.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Jan;20(1):38-41 [8288806.001]
  • [Cites] Br J Dermatol. 1994 Aug;131(2):226-30 [7917987.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):1080-2 [8647978.001]
  • [Cites] Dermatol Surg. 2005 Jul;31(7 Pt 1):784-6 [16029708.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):397-403 [10712886.001]
  • [Cites] Dermatol Surg. 2001 Mar;27(3):246-51 [11277891.001]
  • [Cites] J Am Acad Dermatol. 2005 Oct;53(4):737-9 [16198810.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):1088-90 [11880448.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):707-10 [10871930.001]
  • [Cites] J Clin Immunol. 2004 Jul;24(4):379-88 [15163894.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):140-54 [14526203.001]
  • [Cites] Dermatol Surg. 2003 Sep;29(9):984-6 [12930348.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1570-7 [12771924.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):385-93 [12637918.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [ErratumIn] Br J Dermatol. 2007 Dec;157(6):1304
  • (PMID = 17634082.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18990
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ EMS55131; NLM/ PMC3935457
  •  go-up   go-down


20. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol; 2010 May 10;28(14):2418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
  • PATIENTS AND METHODS: Cancer and Leukemia Group B study CALGB 49907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with early-stage breast cancer.
  • Adherence was calculated as the number of doses taken divided by doses expected, taking into account toxicity-related dosing changes.
  • Adherence was not related to age, tumor stage, or hormone receptor status.
  • CONCLUSION: Most older women with early-stage breast cancer were adherent to short-term oral chemotherapy in a randomized clinical trial.

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):322-8 [11208822.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2423-9 [20385997.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):652-61 [11983753.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2680-8 [12039930.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):602-6 [12586795.001]
  • [Cites] JAMA. 1989 Jun 9;261(22):3273-7 [2716163.001]
  • [Cites] Prev Med. 1991 Jan;20(1):132-46 [2008422.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1189-97 [8501505.001]
  • [Cites] AIDS. 1998 Dec 3;12(17):2295-303 [9863872.001]
  • [Cites] Oncology. 2006;71(1-2):1-9 [17344666.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):549-55 [18071188.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):556-62 [18180462.001]
  • [Cites] Value Health. 2008 Jan-Feb;11(1):44-7 [18237359.001]
  • [Cites] Clin Nurs Res. 2008 May;17(2):89-97 [18387881.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1763-8 [18985046.001]
  • [Cites] CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66 [19147869.001]
  • [Cites] N Engl J Med. 2009 May 14;360(20):2055-65 [19439741.001]
  • [Cites] Breast Cancer Res Treat. 2009 Oct;117(3):615-23 [19294501.001]
  • [Cites] Clin Ther. 2001 Aug;23(8):1296-310 [11558866.001]
  • (PMID = 20368559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA77202; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / .CA31946; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U10 CA025224
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2881723
  •  go-up   go-down


21. Fill S, Taran A, Schulz HU, Kahl S, Kalinski T, Smith B, Costa SD: Sister Mary Joseph's nodule as the first sign of pregnancy-associated gastric cancer: a case report. World J Gastroenterol; 2008 Feb 14;14(6):951-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as the first sign of pregnancy-associated gastric cancer: a case report.
  • Sister Mary Joseph's nodule is an inconspicuous and uncommon clinical sign of advanced malignant disease, especially gastric cancer.
  • Pregnancy-associated gastric cancer is an extremely rare condition and can be difficult to diagnose, due to the absence or misinterpretation of symptoms as pregnancy-related.
  • Diagnostic aids, such as a basic chemistry panel and imaging techniques, may not show any abnormalities.
  • We present a case of a 37-year-old pregnant patient whose umbilical nodule was the first presenting physical sign of gastric cancer, which had metastasized throughout the abdominal and pelvic regions.
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):233-7 [10782897.001]
  • [Cites] Arch Gynecol Obstet. 2006 Apr;274(1):47-9 [16283407.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1249-55 [14750645.001]
  • [Cites] Hautarzt. 2004 Feb;55(2):186-9 [14968331.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] J Chronic Dis. 1966 Oct;19(10):1113-7 [5966767.001]
  • [Cites] World J Surg. 1991 Mar-Apr;15(2):293-7, discussion 298 [2031366.001]
  • [Cites] Arch Dermatol. 1992 Apr;128(4):548-9, 551-2 [1580666.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):3-6 [8289449.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):191-5 [7898116.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):151-4 [8781704.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1273-80 [8908562.001]
  • [Cites] Cutis. 1997 Dec;60(6):297-8 [9426970.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1641-5 [9427036.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):25-33 [9655289.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1913 [15872206.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Apr 25;107(2):208-9 [12648871.001]
  • (PMID = 18240358.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687068
  •  go-up   go-down


22. Harper CE, Patel BB, Cook LM, Wang J, Shirai T, Eltoum IA, Lamartiniere CA: Characterization of SV-40 Tag rats as a model to study prostate cancer. BMC Cancer; 2009 Jan 26;9:30
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of SV-40 Tag rats as a model to study prostate cancer.
  • BACKGROUND: Prostate cancer is the second most frequently diagnosed cancer in men.
  • Animal models that closely mimic clinical disease in humans are invaluable tools in the fight against prostate cancer.
  • This model, however, has not been extensively characterized; hence we have investigated the ontogeny of prostate cancer and determined the role of sex steroid receptor and insulin-like growth factor-1 (IGF-1) signaling proteins in the novel SV-40 Tag rat.
  • Immunoassay techniques were employed to measure cell proliferation, apoptosis, and sex steroid receptor and growth factor signaling-related proteins.
  • RESULTS: Prostatic intraepithelial neoplasia (PIN) and well-differentiated prostate cancer developed as early as 2 and 10 weeks of age, respectively in the ventral prostate (VP) followed by in the dorsolateral (DLP).
  • CONCLUSION: The rapid development of PIN and prostate cancer in conjunction with the large prostate size makes the SV-40 Tag rat a useful model for studying prostate cancer.
  • This study provides evidence of the role of sex steroid and growth factor proteins in prostate cancer development and defines appropriate windows of opportunity for preclinical trials and aids in the rational design of chemoprevention, intervention, regression, and therapeutic studies using prostate cancer rodent models.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1999 Dec;54(6):1112-9 [10604719.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2203-8 [10786685.001]
  • [Cites] Methods Mol Biol. 2000;149:III-IV, 1-413 [11028258.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4693-700 [11406539.001]
  • [Cites] Reprod Fertil Dev. 2001;13(4):241-52 [11800163.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):463-7 [11895861.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):153-7 [12708490.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):171-80 [15149738.001]
  • [Cites] J Endocrinol. 1968 Apr;40(4):485-91 [5643421.001]
  • [Cites] Science. 1974 Dec 27;186(4170):1213-5 [4432067.001]
  • [Cites] Arch Int Physiol Biochim. 1975 May;83(2):239-53 [54056.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] Cell. 1979 May;17(1):43-52 [222475.001]
  • [Cites] Acta Endocrinol (Copenh). 1981 Jan;96(1):127-35 [7456981.001]
  • [Cites] Cell. 1988 Jul 15;54(2):275-83 [2839300.001]
  • [Cites] J Histochem Cytochem. 1989 Jan;37(1):105-13 [2461979.001]
  • [Cites] Cell. 1990 Jan 12;60(1):167-76 [2153055.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26 [8757191.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82 [8855837.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):180-6 [9069255.001]
  • [Cites] J Urol. 1997 Jul;158(1):222-7 [9186364.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Br J Cancer. 1997;76(9):1115-8 [9365156.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):911-5 [9637140.001]
  • [Cites] Endocrinology. 1999 May;140(5):1984-9 [10218945.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63 [10318905.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):930-4 [10362098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]
  • [Cites] Natl Cancer Inst Monogr. 1963 Oct;12:1-27 [14072991.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):148-64 [15389804.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):221-6 [15819720.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1109-16 [15731164.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:1-13 [17261752.001]
  • [Cites] Cancer Sci. 2007 Apr;98(4):471-7 [17284254.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1576-89 [17705241.001]
  • (PMID = 19171036.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 47888; United States / NCI NIH HHS / CA / NIH-NCI-P20-CA93753-03
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Neoplasm Proteins; 0 / probasin; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 5H7I2IP58X / boldenone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2639608
  •  go-up   go-down


23. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidrug resistance (MDR) is a challenge in cancer treatment.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R: TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer; 2006 May 22;94(10):1428-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour growth is tightly related to new blood vessel formation, tissue remodelling and invasiveness capacity.
  • A number of tissular factors fuel the growth of glioblastoma multiforme, the most aggressive brain neoplasm.
  • In fact, gene array analyses demonstrated that the proapoptotic cytokine tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) inhibited mRNA expression of VEGF, along with those of matrix metalloproteinase-2 (MMP-2), its inhibitor tissue inhibitor of matrix metalloproteinases-2 (TIMP-2), as well as the tumour invasiveness-related gene secreted protein acid rich in cysteine (SPARC) in different human glioblastoma cell lines.
  • Moreover, the expression of MMP-2, its inhibitor TIMP-2 and the tumour invasiveness-related protein SPARC were effectively inhibited by TRAIL in glioblastoma cell lines.
  • [MeSH-minor] Animals. Blotting, Western. Cell Survival. Endothelium, Vascular / drug effects. Enzyme-Linked Immunosorbent Assay. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Mice. Mice, Inbred C57BL. Oligonucleotide Array Sequence Analysis. Osteonectin / genetics. Osteonectin / metabolism. RNA, Messenger / metabolism. TNF-Related Apoptosis-Inducing Ligand. Tissue Inhibitor of Metalloproteinase-2 / genetics. Tissue Inhibitor of Metalloproteinase-2 / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6270-7 [12414657.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):213-26 [12510773.001]
  • [Cites] Circulation. 2003 May 6;107(17):2250-6 [12668516.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 May;278(5):L1045-50 [10781437.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] EXS. 2005;(94):209-31 [15617481.001]
  • [Cites] Kidney Int. 2005 Feb;67(2):449-57 [15673292.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):233-43 [15711939.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1273-81 [15809718.001]
  • [Cites] J Vasc Res. 2005 Jul-Aug;42(4):337-47 [15985761.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):261-8 [10861485.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):827-8 [11022932.001]
  • [Cites] Pediatr Neurosurg. 2000 Jul;33(1):49-55 [11025423.001]
  • [Cites] Acta Pharmacol Sin. 2000 Mar;21(3):211-4 [11324417.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1362-9 [11350907.001]
  • [Cites] J Cell Physiol. 2001 Nov;189(2):197-206 [11598905.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):213-35 [11716072.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 [12787570.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4181-7 [12874024.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1526-33 [12874246.001]
  • [Cites] Lab Invest. 2004 Jan;84(1):8-20 [14631378.001]
  • [Cites] Cancer Treat Res. 2004;117:219-48 [15015563.001]
  • [Cites] Neoplasia. 2004 Jul-Aug;6(4):364-73 [15256058.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2474-83 [15353300.001]
  • [Cites] Cancer Sci. 2004 Oct;95(10):840-4 [15504253.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Acta Neuropathol. 1987;72(3):207-13 [3564901.001]
  • [Cites] J Cell Biochem. 1992 Jul;49(3):272-83 [1644864.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):519-28 [1279270.001]
  • [Cites] AIDS. 1994 Sep;8(9):1237-44 [7528513.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):121-9 [7705924.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):298-307 [7616276.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15074-83 [8663054.001]
  • [Cites] EXS. 1997;79:47-64 [9002220.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Urol. 1997 Jun;157(6):2329-33 [9146665.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6B):4163-72 [9428350.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e261-9 [12456313.001]
  • (PMID = 16622457.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / Osteonectin; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ PMC2361261
  •  go-up   go-down


25. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


26. Catrina SB, Lewitt M, Massambu C, Dricu A, Grünler J, Axelson M, Biberfeld P, Brismar K: Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer; 2005 Apr 25;92(8):1467-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a highly vascular tumour and is the most common neoplasm associated with human immunodeficiency virus (HIV-1) infection.
  • The IGF-I receptors (IGF-IR) were identified by immunohistochemistry in biopsies taken from patients with different AIDS/HIV-related KS stages and on KSIMM cells (an established KS-derived cell line).

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1047-53 [10594750.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):325-32 [11114713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8 [11331770.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):373-82 [12044013.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):117-23 [12086869.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):934-6 [12228167.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39684-95 [12138094.001]
  • [Cites] Endocrine. 2002 Dec;19(3):239-48 [12624423.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):527-35 [15141010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Feb;83(3):664-8 [3003744.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Jun;124(6):620-9 [2068892.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1251-8 [1750501.001]
  • [Cites] Endocrinology. 1992 Aug;131(2):890-5 [1379166.001]
  • [Cites] J Endocrinol. 1992 Aug;134(2):169-76 [1383373.001]
  • [Cites] J Immunol Methods. 1996 Jan 16;189(1):117-27 [8576573.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1874-9 [8620507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] AIDS. 1997 May;11(6):713-21 [9143602.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] FASEB J. 1999 Apr;13(6):647-55 [10094925.001]
  • [Cites] Life Sci. 1999;65(10):1047-57 [10499872.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4384-8 [12907608.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):236-42 [14729630.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4136-43 [14627715.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):201-2 [15050909.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):221-30 [15050914.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1390-5 [10581081.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:28-31 [10804088.001]
  • (PMID = 15812560.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Somatomedins; 0 / Vascular Endothelial Growth Factor A; 0F35AOI227 / picropodophyllin; EC 2.7.10.1 / Receptor, IGF Type 1; L36H50F353 / Podophyllotoxin
  • [Other-IDs] NLM/ PMC2362008
  •  go-up   go-down


27. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS: Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer; 2010 Apr 1;126(7):1732-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burkitt lymphoma (BL) is a unique B-cell non-Hodgkin lymphoma with 3 established clinical-epidemiological variants: endemic, sporadic and AIDS-related BL.
  • Therefore, we examined population-based BL incidence patterns in the United States to determine age-related risk.
  • The tri/bimodal incidence pattern was present in sensitivity analyses excluding registries with many HIV/AIDS cases and in period-specific, cohort-specific analyses.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. SEER Program. Survival Rate. Time Factors. United States / epidemiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 UICC.
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Biometrics. 1995 Sep;51(3):874-87 [7548706.001]
  • [Cites] Am J Epidemiol. 1996 Jan 1;143(1):85-91 [8533751.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]
  • [Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]
  • [Cites] N Engl J Med. 1981 Sep 24;305(13):735-45 [7022215.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Br J Cancer. 1963 Mar;17:50-5 [14001942.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 [19066264.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61 [19622723.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] MMWR Suppl. 1987 Dec 25;36(7):1S-20S [2826984.001]
  • [Cites] Annu Rev Public Health. 1991;12:425-57 [2049144.001]
  • [Cites] Am J Epidemiol. 1987 Oct;126(4):578-86 [3631049.001]
  • (PMID = 19810101.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / ZIA CP010176-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS146203; NLM/ PMC2818154
  •  go-up   go-down


28. Volkow P, Zinser JW, Correa-Rotter R: Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol; 2007;8:6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Imatinib is a tyrosine-kinase inhibitor; for which there is limited information regarding its effects on AIDS Kaposi's sarcoma and none in patients with transplant-associated Kaposi's sarcoma.
  • Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi's sarcoma associated with renal graft.
  • CASE PRESENTATION: Here we report a case of an 80 year old male, who developed Kaposi's Sarcoma nine months after receiving a living non-related donor kidney transplant at age 74.
  • [MeSH-minor] Aged, 80 and over. Benzamides. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Imatinib Mesylate. Immunohistochemistry. Kidney Failure, Chronic / diagnosis. Kidney Failure, Chronic / surgery. Male. Neoplasm Staging. Retreatment. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1995 Mar;146(3):727-34 [7887453.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):332-4 [7547414.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1999-2008 [8669484.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):964-6 [15848592.001]
  • [Cites] Int J STD AIDS. 2006 Sep;17(9):571-8 [16942647.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2592-7 [15197801.001]
  • [Cites] J Invest Dermatol. 1990 Dec;95(6 Suppl):176S-179S [2258634.001]
  • [Cites] Rev Med Interne. 1990 Jul-Aug;11(4):322-4 [2096440.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1779-83 [8348508.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):890-4 [8408835.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • (PMID = 17386117.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1852096
  •  go-up   go-down


29. Kreuter A, Rasokat H, Klouche M, Esser S, Bader A, Gambichler T, Altmeyer P, Brockmeyer NH: Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest; 2005;23(8):653-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Classic Kaposi's sarcoma (KS) is a rare neoplasm, predominantly occurring in older subjects of Eastern Europe or Mediterranean descent.
  • Several studies reported the effectiveness of pegylated liposomal doxorubicin (PLD) and low-dose recombinant interferon alfa-2a (IFNalpha) in the treatment of AIDS-associated KS.
  • Neutropenia (33 percent) related to PLD was the most common adverse event (4/12).
  • Flu-like symptoms in 3 patients (50 percent) related to IFNalpha were the most common adverse events.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377582.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 80168379AG / Doxorubicin
  •  go-up   go-down


30. Ye ZB, Ma T, Li H, Jin XL, Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1747-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of IL-12 and IL-18 from 50 samples of gastric cancer tissue were analyzed by immunohistochemistry, and microvessel density (MVD) was determined with microscopic imaging analysis system.
  • IL-12 was significantly associated with pathologic differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage, and IL-18 was closely related to distant metastasis.
  • Intratumoral IL-12 and IL-18 expressions were not statistically related to MVD scoring.
  • CONCLUSION: The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1999 Dec;13(15):2195-202 [10593867.001]
  • [Cites] Int J Urol. 2004 Aug;11(8):647-52 [15285756.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):126-9 [11471895.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Aug;26(4):302-6 [11559342.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2050-5 [11596019.001]
  • [Cites] Auris Nasus Larynx. 2004 Sep;31(3):239-45 [15364358.001]
  • [Cites] In Vivo. 1993 May-Jun;7(3):265-9 [8357968.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):38-43 [8847724.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):817-24 [9120387.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5070-7 [10227975.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43 [16060834.001]
  • [Cites] Cytokine. 2002 Aug 7;19(3):126-37 [12242079.001]
  • [Cites] FASEB J. 2003 Apr;17(6):728-30 [12594171.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):91-5 [14630085.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 [10639148.001]
  • (PMID = 17461482.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4146958
  •  go-up   go-down


31. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ: Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J; 2010;37(4):457-60
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular rupture due to HIV-associated T-cell lymphoma.
  • Patients with lymphoma can develop cardiac involvement that includes malignant pericardial effusions and myocardial infiltration, but extensive myocardial invasion by tumor with resultant rupture has been reported only rarely.
  • We report a case of a patient with human immunodeficiency virus and T-cell lymphoma who presented with signs and symptoms that were suggestive of a non-ST-elevation myocardial infarction.
  • Plans were made for cardiac catheterization, but the patient developed thrombocytopenia after the initiation of heparin and eptifibatide.
  • Cardiac catheterization was deferred, and shortly afterwards he had a witnessed cardiac arrest in the hospital and could not be resuscitated.
  • Autopsy revealed transmural infiltration of the myocardium with lymphoma and resultant rupture of the left ventricular free wall.
  • To our knowledge, this is the 1st reported case of left ventricular free-wall rupture due to transmural infiltration by human-immunodeficiency-virus-associated peripheral T-cell lymphoma.We conclude that noncoronary causes of chest pain, including direct myocardial infiltration, should be considered in immunocompromised patients with lymphoma.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1369-77 [14523146.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Eur Heart J. 1987 May;8(5):549-52 [3609049.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):365-8 [11251283.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):498-505 [15782345.001]
  • [Cites] Int J Cardiol. 2007 Apr 25;117(2):e84-5 [17331600.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):1008-11 [18464123.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):75-8 [9760158.001]
  • (PMID = 20844622.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094143
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929872
  • [Keywords] NOTNLM ; Acute coronary syndromes / HIV infections/complications / heart neoplasms/secondary / heart rupture / lymphatic metastasis / lymphoma, AIDS-related / lymphoma, T-cell/pathology / myocardium/pathology / neoplasm invasiveness / pericardium/pathology
  •  go-up   go-down


32. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


33. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, Biberfeld P: HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol; 2005 Jan;32(1):21-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human gamma-herpes virus-8 (HHV-8) was first described in AIDS-related Kaposi's sarcoma (KS) tumour samples.
  • In this study, we report comparative studies on paraffin-embedded biopsies of AIDS-related KS (AKS) and endemic KS (EKS) with regard to HHV-8 content as evaluated using polymerase chain reaction (PCR) and immunohistochemistry.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Antigens, CD34 / analysis. Antigens, Viral / analysis. Cell Count. DNA, Neoplasm / analysis. Humans. Immunohistochemistry. Nuclear Proteins / analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660651.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Viral; 0 / DNA, Neoplasm; 0 / DNA, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  •  go-up   go-down


34. Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL: Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer; 2005 Jul 11;93(1):46-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Cyclosporins / therapeutic use. Doxorubicin / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Humans. Liposomes

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Feb 15;52(4):891-6 [1737351.001]
  • [Cites] Eur J Cancer. 1991;27(12):1639-42 [1816768.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2186-91 [8174126.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):610-8 [8636778.001]
  • [Cites] Cancer Treat Res. 1996;87:3-38 [8886447.001]
  • [Cites] Clin Pharmacol Ther. 1997 Mar;61(3):301-11 [9084455.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47 [9262252.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5246-53 [9393743.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2005-15 [9815591.001]
  • [Cites] Oncology (Williston Park). 1999 May;13(5A):183-7 [10370927.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2939-47 [10537363.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):131-41 [10585596.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):2885-91 [10652569.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1124-34 [10694566.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):832-42 [11157037.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):220-30 [11223552.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):206-12 [11330951.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):32-40 [11552228.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1577-90 [11745237.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):413-8 [11839657.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Oncologist. 2003;8(5):411-24 [14530494.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4724-33 [15269145.001]
  • [Cites] Comput Programs Biomed. 1979 Mar;9(2):115-34 [761456.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1125-32 [1764376.001]
  • [Cites] Pharm Res. 1993 May;10(5):703-8 [8321835.001]
  • (PMID = 15942626.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA091842
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cyclosporins; 0 / Liposomes; 121584-18-7 / valspodar; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2361488
  •  go-up   go-down


35. Lambert M, Gannagé M, Karras A, Abel M, Legendre C, Kerob D, Agbalika F, Girard PM, Lebbe C, Caillat-Zucman S: Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood; 2006 Dec 1;108(12):3871-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared CD8 T-cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, and ORF65) antigens in patients who spontaneously controlled the infection and in patients with posttransplantation, AIDS-related, or classical KS.
  • [MeSH-minor] Aged. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Female. Herpesvirus Vaccines / immunology. Herpesvirus Vaccines / therapeutic use. Humans. Immunotherapy, Adoptive / methods. Male. Middle Aged. Neoplasm Regression, Spontaneous / immunology. Neoplasm Regression, Spontaneous / pathology. Transplants / adverse effects

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926293.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Cancer Vaccines; 0 / Herpesvirus Vaccines
  •  go-up   go-down


36. Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD: Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci; 2008 Feb 26;9:27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, PIs, particularly Nelfinavir, were reported to disrupt Notch signaling in the HIV-related endothelial cell neoplasm, Kaposi's sarcoma.

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. SAQUINAVIR .
  • Hazardous Substances Data Bank. INDINAVIR SULFATE .
  • Hazardous Substances Data Bank. NELFINAVIR MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2000 Jan;25(1):1-6 [10637601.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32227-35 [12794074.001]
  • [Cites] Nature. 1993 Apr 8;362(6420):557-60 [8385271.001]
  • [Cites] Stroke. 1993 Dec;24(12):2121-7 [8248999.001]
  • [Cites] Clin Pharmacokinet. 1997 Mar;32(3):194-209 [9084959.001]
  • [Cites] J Neurobiol. 1997 May;32(5):469-80 [9110259.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):173-81 [12962683.001]
  • [Cites] Bioessays. 2004 Mar;26(3):225-34 [14988924.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):473-9 [15078991.001]
  • [Cites] Genes Cells. 1997 Mar;2(3):213-24 [9189758.001]
  • [Cites] AIDS Treat News. 1997 Aug 15;(No 277):1-4 [11364559.001]
  • [Cites] Virology. 1998 Oct 25;250(2):255-62 [9792836.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48615-9 [15456788.001]
  • [Cites] J Endocrinol. 2004 Dec;183(3):445-54 [15590971.001]
  • [Cites] Cell Mol Neurobiol. 2005 Feb;25(1):181-99 [15962513.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):425-33 [16053514.001]
  • [Cites] Pharm Res. 2005 Aug;22(8):1259-68 [16078135.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8256-65 [16166302.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6333-44 [15940249.001]
  • [Cites] BMC Cell Biol. 2006;7:10 [16507111.001]
  • [Cites] Curr HIV Res. 2006 Jul;4(3):259-66 [16842079.001]
  • [Cites] Microvasc Res. 2006 Jul-Sep;72(1-2):12-9 [16750838.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9252-9 [16982770.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1337-46 [17081104.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):889-95 [17132220.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jan;320(1):291-9 [17038510.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):493-9 [17245228.001]
  • [Cites] Biochem Pharmacol. 2007 May 15;73(10):1573-81 [17328866.001]
  • [Cites] J Pharm Pharmacol. 2007 Jul;59(7):947-53 [17637189.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(3):261-9 [15470273.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1915-27 [10595922.001]
  • [Cites] J Neurosci. 2000 Mar 1;20(5):1657-65 [10684867.001]
  • [Cites] AIDS. 2000 Apr 14;14(6):743-4 [10807198.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):484-92 [11511084.001]
  • [Cites] Dev Cell. 2001 Dec;1(6):725-6 [11740931.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47840-3 [11602580.001]
  • [Cites] J Cell Biol. 2002 Jan 7;156(1):149-60 [11781339.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1095-7 [11884509.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2830-41 [11909975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6 [12011461.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):1006-11 [12123574.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):372-83 [12453432.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):605-8 [12598159.001]
  • [Cites] Semin Cell Dev Biol. 2003 Apr;14(2):113-9 [12651094.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31277-85 [12764143.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(3):287-302 [15470276.001]
  • (PMID = 18302767.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K01 MH071206; United States / NINDS NIH HHS / NS / R21 NS055639; United States / NHLBI NIH HHS / HL / T35HL007491-25; United States / NIMH NIH HHS / MH / R24 MH059745; United States / NIA NIH HHS / AG / T35AG026757; United States / NINDS NIH HHS / NS / NS055639; United States / NIMH NIH HHS / MH / R01 MH062962; United States / NIMH NIH HHS / MH / MH071206; United States / NIA NIH HHS / AG / T35 AG026757; United States / NHLBI NIH HHS / HL / T35 HL007491; United States / NIMH NIH HHS / MH / MH59745; United States / NIMH NIH HHS / MH / MH62962
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C14orf129 protein, human; 0 / HIV Protease Inhibitors; 0 / NOTCH4 protein, human; 0 / Proto-Oncogene Proteins; 0 / Reactive Oxygen Species; 0 / Receptor, Notch1; 0 / Receptors, Notch; 0 / Repressor Proteins; 1406-18-4 / Vitamin E; 5W6YA9PKKH / Indinavir; EC 3.4.23.- / Aspartic Acid Endopeptidases; HO3OGH5D7I / Nelfinavir; L3JE09KZ2F / Saquinavir; O3J8G9O825 / Ritonavir
  • [Other-IDs] NLM/ PMC2268698
  •  go-up   go-down


37. Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB: Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer; 2005 Oct 1;104(7):1381-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Long-term data are needed to evaluate distress and decisional regret as patients experience treatment-related chronic side effects and efficacy outcomes.
  • Decision-making aids or other interventions to reduce decisional difficulty and emotional distress during decision making were indicated.
  • [MeSH-major] Brachytherapy / methods. Neoplasm Invasiveness / pathology. Patient Satisfaction. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Attitude to Health. Decision Making. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Stress, Psychological

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080181.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N: Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer; 2006 Apr 10;94(7):1000-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic and HIV-related clinical and biological parameters were recorded at KS diagnosis (baseline) and every 6 months thereafter.
  • Fourteen deaths occurred after a median follow-up of 37.5 months, eight of which were KS related.
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Viral Load


39. Olivero OA, Vazquez IL, Cooch CC, Ming J, Keller E, Yu M, Borojerdi JP, Braun HM, McKee E, Poirier MC: Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells. Toxicol Sci; 2010 May;115(1):109-17
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An exposure-related increase in the frequency of micronuclei (MN) was observed in cells exposed to either 10 or 800 microM AZT during P(1)-P(14).

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmazie. 2001 Jun;56(6):492-500 [11446172.001]
  • [Cites] Environ Mol Mutagen. 2009 Oct;50(8):718-24 [19562754.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):239-46 [12123744.001]
  • [Cites] Cell Mol Life Sci. 2002 Aug;59(8):1327-46 [12363036.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):743-7 [12736716.001]
  • [Cites] Life Sci. 2004 Jan 2;74(7):835-42 [14659972.001]
  • [Cites] Environ Mol Mutagen. 2004;43(1):3-9 [14743340.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):63-9 [15013700.001]
  • [Cites] Mutagenesis. 2004 Jul;19(4):307-11 [15215330.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(2):155-67 [15371631.001]
  • [Cites] Environ Mol Mutagen. 2004;44(4):321-8 [15476197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7 [2430286.001]
  • [Cites] N Engl J Med. 1987 Jul 23;317(4):192-7 [3299090.001]
  • [Cites] J Biol Chem. 1988 Jan 5;263(1):375-82 [3335503.001]
  • [Cites] N Engl J Med. 1989 Sep 14;321(11):726-38 [2671731.001]
  • [Cites] Clin Lab Haematol. 1990;12(2):177-84 [2208948.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Oct 30;188(2):712-8 [1359886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2960-4 [8464912.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Dec;6(12):1287-96 [8254464.001]
  • [Cites] Toxicol Lett. 1994 Feb 1;70(2):235-42 [7905210.001]
  • [Cites] Mutat Res. 1994 Apr;321(1-2):113-8 [7510839.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Jul;11(7):805-11 [7546907.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jan 1;8(1):1-9 [8548339.001]
  • [Cites] Mutat Res. 1996 Jul 5;368(3-4):301-7 [8692236.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Feb 10;12(3):223-8 [8835200.001]
  • [Cites] Mutat Res. 1997 May 23;390(3):223-31 [9186571.001]
  • [Cites] Biochem Pharmacol. 1998 Aug 1;56(3):389-95 [9744577.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004;23(11):1797-811 [15598079.001]
  • [Cites] New Microbiol. 2004 Apr;27(2 Suppl 1):63-9 [15646066.001]
  • [Cites] Mutat Res. 2005 Mar 1;570(2):227-35 [15708581.001]
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):215-23 [16395695.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 15;228(2):158-64 [18206198.001]
  • [Cites] Cardiovasc Toxicol. 2008 Summer;8(2):57-69 [18446447.001]
  • [Cites] Med Res Rev. 2008 Sep;28(5):797-820 [18459168.001]
  • [Cites] FEBS J. 2009 Jan;276(2):571-80 [19087190.001]
  • [Cites] Environ Mol Mutagen. 2002;39(4):282-95 [12112380.001]
  • (PMID = 20106944.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA Adducts; 4B9XT59T7S / Zidovudine; 9007-49-2 / DNA; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2855349
  •  go-up   go-down


40. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR: AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol; 2010 Jun 01;28(16):e250-1
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma of the gastrointestinal tract.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. Doxorubicin / therapeutic use. Drug Therapy, Combination. Follow-Up Studies. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / etiology. Gastrointestinal Neoplasms / pathology. HIV Infections / complications. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Severity of Illness Index. Treatment Outcome


41. Parekh S, Hebert T, Ratech H, Sparano J: Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum. J Clin Oncol; 2005 Nov 1;23(31):8116-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Burkitt Lymphoma / pathology. Cecal Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]
  • (PMID = 16258111.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down






Advertisement